Quoin Pharmaceuticals to Announce First Quarter 2024 Financial Results on May 9, 2024
Quoin Pharmaceuticals to Announce First Quarter 2024 Financial Results on May 9, 2024
ASHBURN, Va., May 02, 2024 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the "Company" or "Quoin"), a clinical stage specialty pharmaceutical company focused on rare and orphan diseases, announced today that the Company plans to release its first quarter 2024 financial results before the market opens on Thursday, May 9, 2024.
弗吉尼亞州阿什本，2024年5月2日（環球新聞專線）——專注於罕見病和孤兒病的臨床階段專業製藥公司Quoin Pharmicals Ltd.（納斯達克股票代碼：QNRX）（“公司” 或 “Quoin”）今天宣佈，該公司計劃在2024年5月9日星期四開市前發佈其2024年第一季度財務業績。
The announcement will provide an operational update regarding the company's achievements during the quarter, and will detail financial highlights.
該公告將提供有關公司在本季度業績的最新運營情況，並將詳細介紹財務摘要。
About Quoin Pharmaceuticals Ltd.
關於 Quoin 製藥有限公司
Quoin Pharmaceuticals Ltd. is a clinical stage specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. We are committed to addressing unmet medical needs for patients, their families, communities and care teams. Quoin's innovative pipeline comprises four products in development that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Scleroderma, Epidermolysis Bullosa and others. For more information, visit: www.quoinpharma.com or LinkedIn for updates.
Quoin Pharmicals Ltd. 是一家臨床階段的專業製藥公司，專注於開發和商業化治療罕見病和孤兒病的治療產品。我們致力於解決患者、他們的家人、社區和護理團隊未得到滿足的醫療需求。Quoin的創新產品線包括四種正在開發的產品，這些產品共同有可能靶向大量罕見和孤兒適應症，包括內瑟頓綜合徵、皮膚脫皮綜合徵、掌足角化病、硬皮病、大皰性表皮鬆解症等。欲了解更多信息，請訪問： www.quoinpharma.com 要麼 領英 用於更新。
For further information, contact:
Investor Relations
PCG Advisory
Jeff Ramson
jramson@pcgadvisory.com
(646) 863-6341
欲了解更多信息，請聯繫：
投資者關係
PCG 諮詢
傑夫·拉姆森
jramson@pcgadvisory.com
(646) 863-6341